Member Info for Laura2022

L200

What a strange 1st post on CODE having never posted, account for 14yrs and pretty much silent months on end

Mmmmmm

Tje volatility is due.to the lack.of free.float

The good news keeps coming, going well from 1.25p

Full.ask today and yesterday and now the buying limits have been cut dramatically

After 3mths of flattening it looks likely to breakout through 0.3p for the first time since the placing in Feb

Wadagora

Good morning

TCF could offer.a good bio tech prospect

The 1mln was a buy

OX1 asset: TCF’s Ox-1 asset was brought in-house following the acquisition of Chronos Therapeutics

(for further details see our March 2024 report). Studies have shown that Ox-1 plays an important role

across a range of neuropsychiatric conditions such as anxiety, impulse and substance use disorders,

significant markets which remain underserved by existing treatment options. Additionally, there is a

renewed positive market sentiment in neuroscience drug development, evidenced by a number of

notable M&A transactions over the past 12-18 months, including most recently J&J’s (January 2025)

$14.6bn acquisition of CNS specialist, Intra-Cellular Therapies.

We're heading to the ASCPT 2025 Annual Meeting in Washington, DC (28–30 May)!

Mark Davies and Hayley Close are eager to connect with leaders in clinical pharmacology, PK/PD, and quantitative science. We're looking forward to discussing how Physiomics plc's data-driven approach to model-informed drug development (MIDD) can help accelerate smarter decision-making and streamline the development process across preclinical, clinical, and regulatory stages.

The theme of the 2025 Annual Meeting – 'Patient-Centric Clinical Pharmacology: A Journey from Discovery to Recovery' – reflects our commitment to improving patient outcomes through better-informed strategies. With our expertise in PK/PD, QSP, biostatistics, and data science, we’re ready to share how we optimise dosing strategies, refine clinical trial designs, and enhance regulatory submissions to deliver safer, more effective treatments.

10p paid

Now 130% up after buying on the day of the funding

Here 9p

Steve

At least 6mths ago

It's on the VELA rns rto

Bought a small amount, will see what TR1 holders do

Steady buying all today and Friday

Yes Aklee

I'm holding from my 1.95-2 2p buys

Banking license H1

Hepran

Well done here

TCF could be next pharma with US interest

Purchased a small amount more (£1,000) and will show as a sell

Shows where TCF could head with asset news

Hello NMH

It just looks such a fantastic opportunity and with them presenting lead asset on 11th June

EGTP

I'm up 100% on COIN ICON lets hope FPP is 3rd one in a row

Nai

Also buying TCF